Department of Thoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Thorac Cancer. 2022 Oct;13(19):2767-2775. doi: 10.1111/1759-7714.14617. Epub 2022 Aug 23.
The significance of postoperative adjuvant radiotherapy (PORT) on the survival of resected IIIA-N2 non-small cell lung cancer (NSCLC) remains controversial. Here, we aimed to determine the predictive value of the three nodal classifications which might aid in PORT decision-making.
A total of 4797 patients with stage IIIA-N2 resected NSCLC were identified in the Surveillance, Epidemiology and End Results (SEER) database and were grouped by whether PORT was administered. Survival analysis was used to identify the patient groups who can benefit from PORT. Multivariate analysis was performed to confirm the independent risk factors for lung cancer-specific survival (LCSS) and overall survival (OS). A validation cohort of 1184 patients from three medical centers in China were also included.
PORT was not associated with better LCSS and OS in the entire cohort after propensity score matching (PSM). However, in the subgroups of positive lymph nodes 4 (PLN4), lymph node ratio 4 (LNR4), and log odds of positive lymph nodes 4 (LODDS4), PORT exhibited its role in improving LCSS (p < 0.05). Although the three nodal classifications were all identified as independent predictors of LCSS and OS, LODDS classification had the best discriminatory ability and prognostic accuracy for stage IIIA-N2 patients. Similar results were also obtained in the validation cohort.
The LODDS classification not only exhibited the best prognostic performance in predicting LCSS and OS in stage IIIA-N2 disease, but also could help tailor individualized PORT.
术后辅助放疗(PORT)对可切除 IIIA-N2 期非小细胞肺癌(NSCLC)患者生存的意义仍存在争议。在此,我们旨在确定三种淋巴结分类的预测价值,这些分类可能有助于 PORT 决策。
在 Surveillance, Epidemiology and End Results(SEER)数据库中确定了 4797 例可切除 IIIA-N2 期 NSCLC 患者,并根据是否进行 PORT 分组。生存分析用于确定可能从 PORT 中获益的患者群体。多变量分析用于确认肺癌特异性生存(LCSS)和总生存(OS)的独立危险因素。还纳入了来自中国三个医学中心的 1184 例验证队列患者。
在倾向评分匹配(PSM)后,PORT 与整个队列的 LCSS 和 OS 无显著相关性。然而,在阳性淋巴结 4(PLN4)、淋巴结比率 4(LNR4)和阳性淋巴结对数 odds 4(LODDS4)的亚组中,PORT 显示出改善 LCSS 的作用(p < 0.05)。尽管三种淋巴结分类均被确定为 LCSS 和 OS 的独立预测因素,但 LODDS 分类对 IIIA-N2 期患者的预测能力和预后准确性最佳。在验证队列中也得到了类似的结果。
LODDS 分类不仅在预测 IIIA-N2 期疾病的 LCSS 和 OS 方面表现出最佳的预后性能,而且还可以帮助制定个体化的 PORT。